for glucose and lipid management
2. Yin J, Xing H, Ye J (May 2008). “Efficacy of Berberine in patients with type 2 diabetes mellitus”. Metabolism: Clinical and Experimental 57 (5) 712–7.
3. Zhang Y et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid Berberine. J Clin Endocrinol Metab. 2008 Jul; 93(7) 2559-65.
4. Di Pierro F et al. Pilot study on the additive effects of Berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes. 2012; 5:213-7.
5. Dong H et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012; 2012:591654.
6. Wei et al. A clinical study on the short-term effect of Berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012 Jan; 166(1):99-105.
7. Lee YS et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin resistant states.Diabetes. 2006 Aug; 55(8):2256-64.
8. Turner N et al. Berberine and its more biologically available derivative, dihydroBerberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of Berberine to activate AMP-activated protein kinase and improve insulin action.Diabetes. 2008 May; 57(5):1414-8.
9. Chen C et al. Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun. 2010 Jul 2; 397(3):543-7.
10. Cok A et al. Berberine acutely activates the glucose transport activity of GLUT1. Biochimie. 2011 Jul;93(7):1187-92.
11. Kong WJ et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism. 2009 Jan; 58(1):109-19.
12. Zhang H et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010 Feb; 59(2):285-92.
13. Yu Y et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol. 2010 Apr 1; 79(7):1000-6.
14. Yang J et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med 2012; 2012:363845.
15. Wei W et al. A clinical study on the short-term effect of Berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012 Jan; 166(1):99-105.
16. Pham TP, Kwon J, Shin J. Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2. Biochem Biophys Res Commun. 2011 Sep 23; 413(2):376-82.
17. Zhang Y et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid Berberine. J. Clin. Endocrinol Metab. 2008 Jul; 93(7)2559-65.
18. Cicero et al. A controlled study was conducted in patients who had hypercholesterolaemia and hypertriglyceridaemia, administering 500 mg of berberine a single dose once a day 2006-2007.
19. Kong W et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004 Dec 10(12):1344-51.
20. Li H et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009 Oct 16; 284(42):28885-95.
21. Cicero et al Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. Nutrition and Dietary Supplements 2009:1 110.
22. 23. Pirillo et al-Effetti della berberina nella sindrome metabolica: risultati di uno studio clinico Effects of berberine on metabolic syndrome: results from a clinical study. Giornale Italiano dell’Arteriosclerosi 2014; 5 (2): 53-62.
24. Sharma S et al. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes.J Trace Elem Med Biol. 2011 Jul; 25(3):149-53.
25. Cefalu WT et al. Newcomer B. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. 2010 May; 59(5):755-62.
26. Patal P. C. et al. A Meta-analysis on the Effect of Chromium Picolinate on Glucose and Lipid Profiles Among Patients with Type 2 Diabetes Mellitus. Philippine Journal of Internal Medicine Volume 48 Number 1 January-June, 2010.
27. Ferrara LA et al. Olive oil and reduced need for antihypertensive medications. Arch Intern Med. 2000 Mar 27;160(6):837-42.
28. Bogani, P. et al. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis 2007, 190, 181–186.
29. Ascaso JF et al. Effect of dietary olive oil on plasma high density ipoproteins. Rev Clin Esp. 1987 May; 180(9):486-8.
30. De Lorgeril M et al. The Mediterranean-style diet for the prevention of cardiovascular diseases.Public Health Nutr. 2006;9(1A):118.
31. Zhang X et al. Hydroxytyrosol inhibits pro-inflammatory cytokines, iNOS, and COX-2 expression in human monocytic cells. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun; 379(6):581-6.
32. Fito, M. et al. Protective effect of olive oil and its phenolic compounds against low density lipoprotein oxidation. Lipids. 2000. 35: 633–638.
33. Fito, M. et al. Anti-inflammatory effect of virgin olive oil in stable coronary dis- ease patients: a randomized, crossover, controlled trial. Eur. J. Clin. Nutr. 2008, 62, 570–574.
34. González-Santiago M et al. One-month administration of hydroxytyrosol, a phenolic antioxidant present in olive oil, to hyperlipemic rabbits improves blood lipid profile, antioxidant status and reduces atherosclerosis development. Atherosclerosis. 2006 Sep; 188(1):35-42.
35. González-Santiago M et al. Human absorption of a supplement containing purified hydroxytyro- sol, a natural antioxidant from olive oil, and evidence for its transient association with low-density lipoproteins. Pharma- col Res. 2010 Apr; 61(4):364-70.
36. Gorinstein, S. et al. Olive oils improve lipid metabolism and increase antioxidant potential in rats fed diets containing cholesterol. J. Agric. Food Chem. 2002, 50, 6102–6108.
37. Moreno-Luna R et al.Olive Oil Polyphenols Decrease Blood Pressure and Improve Endothelial Function in Young Women with Mild Hypertension. Am J Hypertens. 2012 Aug 23.
38. Ramirez-Tortosa MC et al. Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in free-living men with peripheral vascular disease. J Nutr. 1999 Dec; 129(12):2177-83.
39. Ruano, J.et al. Phenolic content of virgin olive oil improves ischemic reactive hyperemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 2005, 46, 1864–1868.
40. Ruano, J. et al. Intake of phenol-rich virgin olive oil improves the postprandial prothrom- botic profile inhypercholesterolemic patients. Am. J. Clin. Nutr. 2007, 86, 341–346.
41. Bendini A et al. Phenolic molecules in virgin olive oils: a survey of their sensory properties, health effects, antioxidant activity and analytical methods. An overview of the last decade. Molecules. 2007 Aug 6; 12(8)1679-719.
42. Aunon-Calles D et al. Hydroxytyrosol is not genotoxic in vitro. Pharmacological Research 74 (2013) 87– 93.
43. Leger CL et al. A thromboxane effect of a hydroxytyrosol-rich olive oil wastewater extract in patients with uncomplicated type i diabetes. European Journal of Clinical Nutrition2005; 59:727–30.
44. Auñon-Calles D et al. Toxicological evaluation of pure hydroxytyrosol. Food and Chemical Toxicology 55 (2013) 498–504.
45. Scoditti et al. Additive Regulation of Adiponectin Expression by the Mediterranean Diet Olive Oil Components Oleic Acid and Hydroxytyrosol in Human Adipocytes. PLOS ONE | DOI:10.1371/journal.pone.0128218 June 1, 2015.
46. de Bock M, et al. Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo controlled, crossover trial. PLoS One. 2013; 8: e57622.
47. Cao K, Xu J, et al. Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice. Free Radic Biol Med. 2014; 67: 396– 407.